vs
Side-by-side financial comparison of AGIOS PHARMACEUTICALS, INC. (AGIO) and John Marshall Bancorp, Inc. (JMSB). Click either name above to swap in a different company.
AGIOS PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($20.0M vs $16.8M, roughly 1.2× John Marshall Bancorp, Inc.). John Marshall Bancorp, Inc. runs the higher net margin — 36.3% vs -541.1%, a 577.4% gap on every dollar of revenue. Over the past eight quarters, AGIOS PHARMACEUTICALS, INC.'s revenue compounded faster (56.1% CAGR vs 15.3%).
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
John Marshall Bancorp, Inc. is a U.S.-based bank holding company that operates through its wholly owned subsidiary John Marshall Bank. It provides a full suite of commercial and consumer banking products including deposit accounts, commercial loans, residential mortgages, and personal financial services, primarily serving retail customers and small-to-mid-sized businesses across the U.S. Mid-Atlantic region.
AGIO vs JMSB — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $20.0M | $16.8M |
| Net Profit | $-108.0M | $6.1M |
| Gross Margin | 90.6% | — |
| Operating Margin | -608.9% | — |
| Net Margin | -541.1% | 36.3% |
| Revenue YoY | 86.1% | — |
| Net Profit YoY | -11.9% | 26.8% |
| EPS (diluted) | $-1.86 | $0.43 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $16.8M | ||
| Q4 25 | $20.0M | $16.4M | ||
| Q3 25 | $12.9M | $16.3M | ||
| Q2 25 | $12.5M | $15.4M | ||
| Q1 25 | $8.7M | $14.6M | ||
| Q4 24 | $10.7M | $14.3M | ||
| Q3 24 | $9.0M | $13.8M | ||
| Q2 24 | $8.6M | $12.6M |
| Q1 26 | — | $6.1M | ||
| Q4 25 | $-108.0M | $5.9M | ||
| Q3 25 | $-103.4M | $5.4M | ||
| Q2 25 | $-112.0M | $5.1M | ||
| Q1 25 | $-89.3M | $4.8M | ||
| Q4 24 | $-96.5M | $4.8M | ||
| Q3 24 | $947.9M | $4.2M | ||
| Q2 24 | $-96.1M | $3.9M |
| Q1 26 | — | — | ||
| Q4 25 | 90.6% | — | ||
| Q3 25 | 87.0% | — | ||
| Q2 25 | 86.3% | — | ||
| Q1 25 | 87.6% | — | ||
| Q4 24 | 88.3% | — | ||
| Q3 24 | 91.3% | — | ||
| Q2 24 | 82.6% | — |
| Q1 26 | — | — | ||
| Q4 25 | -608.9% | 47.4% | ||
| Q3 25 | -907.4% | 42.2% | ||
| Q2 25 | -1020.1% | 42.7% | ||
| Q1 25 | -1222.0% | 42.4% | ||
| Q4 24 | -1165.3% | 42.5% | ||
| Q3 24 | -1146.9% | 38.8% | ||
| Q2 24 | -1228.3% | 39.7% |
| Q1 26 | — | 36.3% | ||
| Q4 25 | -541.1% | 36.2% | ||
| Q3 25 | -803.1% | 33.2% | ||
| Q2 25 | -899.4% | 33.1% | ||
| Q1 25 | -1023.3% | 32.9% | ||
| Q4 24 | -899.6% | 33.3% | ||
| Q3 24 | 10574.7% | 30.7% | ||
| Q2 24 | -1115.7% | 30.9% |
| Q1 26 | — | $0.43 | ||
| Q4 25 | $-1.86 | $0.41 | ||
| Q3 25 | $-1.78 | $0.38 | ||
| Q2 25 | $-1.93 | $0.36 | ||
| Q1 25 | $-1.55 | $0.34 | ||
| Q4 24 | $-1.44 | $0.33 | ||
| Q3 24 | $16.22 | $0.30 | ||
| Q2 24 | $-1.69 | $0.27 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $89.1M | $150.2M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.2B | $268.1M |
| Total Assets | $1.3B | $2.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $150.2M | ||
| Q4 25 | $89.1M | $130.0M | ||
| Q3 25 | $92.7M | $163.6M | ||
| Q2 25 | $80.9M | $116.9M | ||
| Q1 25 | $79.0M | $169.1M | ||
| Q4 24 | $76.2M | $122.5M | ||
| Q3 24 | $253.7M | $177.2M | ||
| Q2 24 | $84.5M | $182.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | $80.9M | ||
| Q3 25 | — | $80.9M | ||
| Q2 25 | — | $80.8M | ||
| Q1 25 | — | $80.8M | ||
| Q4 24 | — | $80.8M | ||
| Q3 24 | — | $80.8M | ||
| Q2 24 | — | $24.7M |
| Q1 26 | — | $268.1M | ||
| Q4 25 | $1.2B | $265.6M | ||
| Q3 25 | $1.3B | $259.7M | ||
| Q2 25 | $1.4B | $253.7M | ||
| Q1 25 | $1.5B | $253.0M | ||
| Q4 24 | $1.5B | $246.6M | ||
| Q3 24 | $1.6B | $243.1M | ||
| Q2 24 | $660.5M | $235.3M |
| Q1 26 | — | $2.4B | ||
| Q4 25 | $1.3B | $2.3B | ||
| Q3 25 | $1.4B | $2.3B | ||
| Q2 25 | $1.5B | $2.3B | ||
| Q1 25 | $1.6B | $2.3B | ||
| Q4 24 | $1.7B | $2.2B | ||
| Q3 24 | $1.8B | $2.3B | ||
| Q2 24 | $773.1M | $2.3B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.30× | ||
| Q3 25 | — | 0.31× | ||
| Q2 25 | — | 0.32× | ||
| Q1 25 | — | 0.32× | ||
| Q4 24 | — | 0.33× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.11× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-96.2M | — |
| Free Cash FlowOCF − Capex | $-97.3M | — |
| FCF MarginFCF / Revenue | -487.5% | — |
| Capex IntensityCapex / Revenue | 5.6% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-377.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-96.2M | $22.6M | ||
| Q3 25 | $-88.2M | $1.2M | ||
| Q2 25 | $-77.1M | $7.5M | ||
| Q1 25 | $-111.5M | $7.0M | ||
| Q4 24 | $-133.2M | $17.3M | ||
| Q3 24 | $-84.2M | $1.4M | ||
| Q2 24 | $-72.6M | $10.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-97.3M | $22.0M | ||
| Q3 25 | $-89.7M | $1.2M | ||
| Q2 25 | $-78.0M | $7.4M | ||
| Q1 25 | $-112.3M | $6.6M | ||
| Q4 24 | $-134.1M | $16.8M | ||
| Q3 24 | $-84.6M | $1.3M | ||
| Q2 24 | $-72.7M | $10.1M |
| Q1 26 | — | — | ||
| Q4 25 | -487.5% | 134.7% | ||
| Q3 25 | -696.5% | 7.3% | ||
| Q2 25 | -626.2% | 47.8% | ||
| Q1 25 | -1286.4% | 45.3% | ||
| Q4 24 | -1250.1% | 116.9% | ||
| Q3 24 | -944.2% | 9.5% | ||
| Q2 24 | -844.4% | 80.1% |
| Q1 26 | — | — | ||
| Q4 25 | 5.6% | 3.4% | ||
| Q3 25 | 12.1% | 0.2% | ||
| Q2 25 | 7.0% | 1.0% | ||
| Q1 25 | 8.8% | 2.3% | ||
| Q4 24 | 9.0% | 3.4% | ||
| Q3 24 | 4.7% | 0.8% | ||
| Q2 24 | 1.8% | 0.4% |
| Q1 26 | — | — | ||
| Q4 25 | — | 3.82× | ||
| Q3 25 | — | 0.23× | ||
| Q2 25 | — | 1.48× | ||
| Q1 25 | — | 1.45× | ||
| Q4 24 | — | 3.61× | ||
| Q3 24 | -0.09× | 0.33× | ||
| Q2 24 | — | 2.60× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AGIO
Segment breakdown not available.
JMSB
| Net Interest Income | $16.5M | 98% |
| Noninterest Income | $284.0K | 2% |
